Barclays downgrades Hikma to ‘equalweight’ on Generics concerns
Hikma Pharmaceuticals
1,918.50p
16:45 28/03/24
2.02%
38.00p
Barclays downgraded Hikma Pharmaceuticals on Friday to ‘equalweight’ from ‘overweight’ and cut the price target to 1,750p from 2,250p as it said a lack of visibility in the generics division was a real concern.
FTSE 100
7,952.62
17:14 28/03/24
n/a
n/a
FTSE 350
4,383.21
17:14 28/03/24
n/a
n/a
FTSE All-Share
4,338.05
16:50 28/03/24
n/a
n/a
Pharmaceuticals & Biotechnology
21,366.25
17:14 28/03/24
-0.23%
-48.29
On Thursday, Hikma downgraded revenue guidance for the generics segment to between $650m and $675m, from between $710m and $750m.
"Yes, Generics is a small part of Hikma’s business, but it's been dominating the narrative so far this year," Barclays said.
"With yet another downward revision to numbers and without a permanent CEO, we think it is difficult to put new money into the name."